Patents Examined by Marianne P. Allen
  • Combination therapy for neoplasia treatment
    Patent number: 10377828
    Abstract: The present invention relates to an insulin-like growth factor (IGF) receptor antagonist for use in the treatment of prostate neoplasia, including benign prostatic hyperplasia (BPH), prostate cancer, and particularly CRPC, wherein the antagonist is used in combination with an androgen receptor antagonist. An embodiment of the invention is where the androgen receptor antagonist is enzalutamide.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: August 13, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Paul Adam, Katrin Friedbichler
  • Human anti-VEGFR-2/KDR antibodies
    Patent number: 10364291
    Abstract: The invention relates to antibodies that bind to VEGFR-2. The antibodies are used for treating neoplastic diseases, hyperproliferative disorders, and angiogenic disorders and can be used alone or in combination with other agents.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: July 30, 2019
    Assignee: Kadmon Corporation, LLC
    Inventors: Zhenping Zhu, Dan Lu, Zhanna Polonskaya
  • Cytokines and neuroantigens for treatment of immune disorders
    Patent number: 10363306
    Abstract: The present invention provides methods of regulating an immunological disorder comprising administering to a subject an effective amount of (i) an autoimmune antigen in conjunction with (ii) an anti-inflammatory cytokine. Compositions including the same are also provided.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: July 30, 2019
    Assignee: East Carolina University
    Inventor: Mark D. Mannie
  • Chimeric fibroblast growth factor 23 proteins and methods of use
    Patent number: 10364278
    Abstract: The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and the C-terminus includes a C-terminal portion of an FGF23 molecule. The portion of the paracrine FGF is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification. The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, methods for treating a subject suffering from a disorder, and methods of screening for compounds with enhanced binding affinity for the ?Klotho-FGF receptor complex involving the use of chimeric proteins of the present invention.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: July 30, 2019
    Assignee: New York University
    Inventors: Moosa Mohammadi, Regina Goetz
  • Antibody fragments, compositions and uses thereof
    Patent number: 10351628
    Abstract: An isolated nucleic acid encoding a monovalent antibody fragment comprising a first polypeptide comprising a light chain variable domain and two constant domains and a second polypeptide comprising a heavy chain variable domain and two constant domains, wherein two chain constant domains are light chain constant domains and two constant domains are CH1 heavy chain constant domains.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: July 16, 2019
    Assignee: METIS PRECISION MEDICINE SB S.R.L.
    Inventors: Elisa Vigna, Paolo Michieli, Paolo Maria Comoglio
  • Antibodies to IL-6 and use thereof
    Patent number: 10344086
    Abstract: The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: July 9, 2019
    Assignee: ALDERBIO HOLDINGS LLC
    Inventors: Leon F. Garcia-Martinez, Anne Elisabeth Carvalho Jensen, Katie Anderson, Benjamin H. Dutzar, Ethan W. Ojala, Brian R. Kovacevich, John A. Latham, Jeffrey T. L. Smith
  • Fibroblast growth factor muteins with increased activity
    Patent number: 10336799
    Abstract: The present invention provides FGF-2 polypeptides that differ from the wild-type FGF-2 (SEQ ID NO:1) at least at amino acid position 56, 102 and 119, wherein the differences are Q56I, N102G, K119N substitutions, leading to FGF-2 polypeptides with higher thermostability, higher biological activity and higher resistance to proteolytic degradation. These polypeptides can be used in cell culture media.
    Type: Grant
    Filed: April 6, 2015
    Date of Patent: July 2, 2019
    Assignee: Miltenyi Biotec GmbH
    Inventor: Volker Nolle
  • Continuous cell programming devices
    Patent number: 10328133
    Abstract: The present invention comprises compositions, methods and devices for creating an infection-mimicking environment within a polymer scaffold to stimulate antigen-specific dendritic cell activation. Devices of the present invention are used to provide protective immunity to subjects against infection and cancer.
    Type: Grant
    Filed: February 13, 2009
    Date of Patent: June 25, 2019
    Assignees: President and Fellows of Harvard College, Dana-Farber Cancer Institute, Inc.
    Inventors: David J. Mooney, Omar Ali, Glenn Dranoff
  • Antibody against human NRG1 protein
    Patent number: 10323087
    Abstract: An object is to provide an antibody capable of specifically recognizing a human NRG1 protein isoform, and suppressing signal transduction in which the isoform is involved. An antibody capable of binding to a region at positions 221 to 234 of a human NRG1-? protein or an antibody capable of binding to a region at positions 213 to 239 of a human NRG1-?1 protein was successfully obtained. Further, it was also found that these antibodies had an activity of suppressing cleavage of the NRG1 protein, an activity of suppressing phosphorylation of an ErbB3 protein in a cancer cell, and an activity of suppressing in vivo tumor proliferation.
    Type: Grant
    Filed: February 21, 2018
    Date of Patent: June 18, 2019
    Assignee: MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.
    Inventors: Kenichiro Ono, Kasumi Yagi
  • Heavy chain only antibodies to PDGF
    Patent number: 10308711
    Abstract: Disclosed herein are monospecific HCAb antibodies with antigen-binding specificity to PDGF and bispecific antibodies with antigen-binding specificities to PDGF-2 and VEGF or to PDGF and ANG-2.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: June 4, 2019
    Assignee: Allergan, Inc.
    Inventors: Yanbin Liang, Daniel W. Gil
  • Methods for treating metabolic disorders using FGF
    Patent number: 10293027
    Abstract: The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidemia, obesity, and fatty liver.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: May 21, 2019
    Assignee: Salk Institute for Biological Studies
    Inventors: Johan W. Jonker, Michael Downes, Ronald M. Evans, Jae Myoung Suh
  • FGF-18 formulation in xyloglucan gels
    Patent number: 10293051
    Abstract: The invention relates to the field of pharmaceutical formulations. More particularly, it is directed to xyloglucan hydrogels comprising Fibroblast Growth Factor 18 (FGF-18) compounds and methods of producing such hydrogels. The hydrogels of the invention can be used, once formed in situ, for the treatment of cartilage disorders such as osteoarthritis or cartilage injury.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: May 21, 2019
    Assignee: ARES TRADING S.A.
    Inventors: Caterina Lo Presti, Donatella Bulone, Clelia Dispenza
  • Quantifying met protein for cancer treatment
    Patent number: 10288616
    Abstract: Methods are provided for treating a gastric cancer patient. A specific Met fragment peptide is precisely quantitated by SRM-mass spectrometry directly in gastric tumor cells collected from gastric tumor tissue that was obtained from the cancer patient and compared to a reference level. If the Met peptide is below the reference level a second therapeutic regimen is used to treat the patient whereas if the Met peptide is above the reference level then a first therapeutic regimen combining, for example, the second regimen with one or more Met inhibitor therapeutic agents may be used to treat the patient.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: May 14, 2019
    Assignees: Expression Pathology, Inc., The University Of Chicago
    Inventors: Daniel Catenacci, Todd Hembrough, Fabiola Cecchi, Wei-Li Liao
  • Methods for treating an animal
    Patent number: 10279013
    Abstract: Provided herein are methods for treating an animal using a composition that includes active IGF. The methods include treating an animal at risk of having an infection caused by an infectious agent, treating an animal having an infection, and treating a symptom associated with an infection. In one embodiment, the infectious agent is a virus. In one embodiment, the administering includes daily administration of at least 0.05 nanograms of active IGF-1 per kilogram bodyweight of the animal daily (ng/kg), at least 0.1 ng/kg, at least 2 ng/kg, at least 5 ng/kg, or at least 10 ng/kg.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: May 7, 2019
    Assignee: PURETEIN BIOSCIENCE LLC
    Inventors: Brett Casebolt, Chad D. Hagen, Robert Eldon Musser
  • Preparations containing hepatocyte growth factor and hyaluronic acid, and methods of making and using same
    Patent number: 10279075
    Abstract: Preparations containing hepatocyte growth factor (HGF) and hyaluronic acid (HA) and methods of making and using same. The HGF and HA preparations can be prepared together in solution as an injectable fluid without gelatinization, or impregnated within a porous hydrophilic matrix material with, or without, cross-linking of the HA with the matrix material. The preparations can be used as a dermal filler or to generate and promote healing of cartilage, vertebral discs, connective tissues such as tendons and ligaments and bone in vivo.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: May 7, 2019
    Assignee: NUTECH MEDICAL, INC.
    Inventor: Howard P. Walthall, Jr.
  • Diagnosis of cancer by detecting auto-antibodies against vascular endothelial growth factor (VEGF)
    Patent number: 10261087
    Abstract: The present invention relates to a method for diagnosis of a cancer, comprising the steps of (i) determining the level of antibodies against vascular endothelial growth factor (VEGF) in a sample from a subject to be diagnosed, (ii) comparing the determined level in the sample to a control level derived from subjects without cancer; wherein a decreased level in the sample from the subject to be diagnosed as compared to the control level is indicative for cancer in the subject. Furthermore, the invention relates to method of predicting response and outcome of a treatment of a cancer with an angiogenesis inhibitor.
    Type: Grant
    Filed: February 3, 2015
    Date of Patent: April 16, 2019
    Assignee: CELLTREND GMBH
    Inventors: Harald Heidecke, Kai Schulze-Forster
  • Anti-ANGPTL8 antibodies and uses thereof
    Patent number: 10259870
    Abstract: The present invention provides antibodies that bind to ANGPTL8 and methods of using the same. According to certain embodiments, the antibodies of the invention bind human ANGPTL8 with high affinity. The antibodies of the invention may be fully human antibodies. The antibodies of the invention are useful for the treatment of various diseases or disorders characterized in part by elevated blood triglyceride levels.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: April 16, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Viktoria Gusarova, Jesper Gromada, Andrew J. Murphy, David R. Buckler
  • Continuous cell programming devices
    Patent number: 10258677
    Abstract: The present invention comprises compositions, methods, and devices for creating an infection-mimicking environment within a polymer scaffold to stimulate antigen-specific dendritic cell activation. Devices of the present invention are used to provide protective immunity to subjects against infection and cancer.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: April 16, 2019
    Assignees: President and Fellows of Harvard College, Dana-Farber Cancer Institute, Inc.
    Inventors: David J. Mooney, Omar Abdel-Rahman Ali, Glenn Dranoff
  • Polypeptide, anti-VEGF antibody, and anti-c-Met/anti-VEGF bispecific antibodies comprising the same
    Patent number: 10246507
    Abstract: A polypeptide, an anti-VEGF antibody and an anti-c-Met/anti-VEGF bispecific antibody, which includes the polypeptide, a pharmaceutical composition including the antibody, and a method of treating cancer using the antibody.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: April 2, 2019
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Seung Hyun Lee, Soo Yeon Jung, Bo Gyou Kim, Seung Ja Oh, Ji Min Lee
  • Compositions and methods for vascular protection against reperfusion injury after myocardial ischemia
    Patent number: 10239926
    Abstract: As described herein, the present invention features compositions comprising an HGF/IgG complex and methods of using such compositions to reduce ischemic reperfusion injury.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: March 26, 2019
    Assignee: The University of Vermont and State Agriculture College
    Inventor: Jeffrey Spees